Active Ingredient History

NOW
  • Now
Nabiximols is a specific Cannabis extract that was approved in 2010 as a botanical drug in the United Kingdom. Nabiximols is sold as a mouth spray intended to alleviate neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis; it was developed by the UK company GW Pharmaceuticals. In 2019 it was proposed that following application of the spray, nabiximols is washed away from the oral mucosa by the saliva flow and ingested into the stomach, with subsequent absorption from the gastro-intestinal tract. Nabiximols is a combination drug standardized in composition, formulation, and dose. Its principal active cannabinoid components are the cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD.   Wikipedia

  • SMILES: CCCCCc1cc(O)c([C@@H]2C=C(C)CC[C@H]2C(=C)C)c(O)c1.CCCCCc3cc(O)c4[C@@H]5C=C(C)CC[C@H]5C(C)(C)Oc4c3
  • InChIKey: SSNHGLKFJISNTR-DYSNNVSPSA-N
  • Mol. Mass: 628.94
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
gw1000 | gw 1000 | gw-1000 | gw-1000-02 | nabiximols | sativex | tetrahydrocannabinol-cannabidiol combination

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue